Nuria Chic
Grup de recerca
- Genòmica translacional i teràpies dirigides en tumors sòlids Pre-doctoral researcher (R1)
Publicacions destacades
-
Tumor Cellularity and Infiltrating Lymphocytes (CelTIL) as a Survival Surrogate in HER2-Positive Breast Cancer
Autors:Referència: Journal Of The National Cancer Institute 2022. -
Correlative Biomarker Analysis of Intrinsic Subtypes and Efficacy Across the MONALEESA Phase III Studies
Autors:Referència: Journal Of Clinical Oncology 2021. -
Development and validation for research assessment of Oncotype DX® Breast Recurrence Score, EndoPredict® and Prosigna®
Autors:Referència: Npj Breast Cancer 2021. -
Circulating tumor DNA dynamics in advanced breast cancer treated with CDK4/6 inhibition and endocrine therapy
Autors:Referència: Npj Breast Cancer 2021. -
PIK3CA Mutation in the ShortHER Randomized Adjuvant Trial for Patients with Early HER2+ Breast Cancer: Association with Prognosis and Integration with PAM50 Subtype
Autors:Referència: Clinical Cancer Research 2020. -
A multivariable prognostic score to guide systemic therapy in early-stage HER2-positive breast cancer: a retrospective study with an external evaluation
Autors:Referència: Lancet Oncology 2020. -
Frequency and spectrum of PIK3CA somatic mutations in breast cancer
Autors:Referència: Breast Cancer Research 2020. -
HER2-enriched subtype and pathological complete response in HER2-positive breast cancer: A systematic review and meta-analysis
Autors:Referència: Cancer Treatment Reviews 2020. -
Phenotypic changes of HER2-positive breast cancer during and after dual HER2 blockade
Autors:Referència: Nature Communications 2020. -
Different Pathological Complete Response Rates According to PAM50 Subtype in HER2+ Breast Cancer Patients Treated With Neoadjuvant Pertuzumab/Trastuzumab vs Trastuzumab Plus Standard Chemotherapy: An Analysis of Real-World Data.
Autors:Referència: Frontiers In Oncology 2019.
Projectes destacats
-
Desarrollo de un test basado en DNA tumoral circulante (ctDNA) para identificar los subtipos moleculares intrínsecos de cáncer de mama
Finançador: Fundació Clínic per la Recerca Biomèdica (Sede o evento)Durada: 01/02/2020 -
Treatment of advanced breast cancer with adoptive therapy of CD3+/PD1+ tumor infiltrating lymphocytes
Finançador: Hospital Clinic de Barcelona (Sede o evento)Durada: 02/12/2019